Procter & Gamble (PG) Q4 2025 Earnings Transcript

Procter & Gamble posted fiscal 2025 organic sales growth of 2% and core EPS of $6.83, up 4%, while returning $16 billion to shareholders and expanding core operating margin 50 bps despite a 40 bps gross margin decline. The company named Shailesh Jejurikar as incoming CEO effective Jan. 1, 2026, and launched a two-year restructuring targeting up to 7,000 nonmanufacturing role cuts. Fiscal 2026 guidance calls for 0% to 4% organic sales growth, core EPS of $6.83 to $7.09, and about $1 billion in pre-tax tariff costs, highlighting cautious near-term demand and supply-chain uncertainty.

Analysis

PG is signaling that the next leg of earnings will be less about category beta and more about self-help. The succession to Jejurikar looks continuity-preserving rather than disruptive, which matters because the real catalyst is the restructuring: a meaningful cut to nonmanufacturing overhead should widen the operating leverage embedded in the portfolio, but only with a lag. Near term, that makes FY26 look like an investment year where reported margin expansion can be masked by tariffs, capacity spending, and portfolio pruning, even as the underlying earnings power improves into FY27.

The more interesting second-order effect is competitive. If PG keeps widening the gap between innovation leaders and laggards, the pressure shifts onto peers with weaker balance sheets and less pricing credibility. That is likely most painful for UL, KMB, and CLX, where promo intensity can defend share temporarily but usually at the cost of category economics; PG is explicitly choosing not to meet that game head-on. Retailers also look like quiet winners from the migration to lower inventory regimes: less working capital, but more power to force sell-in discipline, which means suppliers with weaker brand pull will feel disproportionate volume pressure.

The tariff framework is the key swing factor, but the market may be over-indexing on the absolute dollar amount and under-indexing on pricing elasticity. PG is effectively saying it can pass through a meaningful portion without wrecking demand because the portfolio is anchored in daily-use, low-elasticity purchases; the bigger risk is not tariff pass-through, it is consumer deceleration compounding retailer destocking. That creates a setup where the stock can de-rate on weak quarterly prints even if the multi-year earnings trajectory is intact. The contrarian view is that a wider guidance range is not a sign of deteriorating quality but of management choosing to preserve upside optionality while the restructuring creates an earnings inflection later in the fiscal year.

Key Decisions for Investors

• Long PG vs short UL or KMB over the next 6-12 months: PG has better pricing power, more credible innovation, and cleaner self-help; downside is valuation compression if category growth slows further.
• Buy PG on post-print weakness rather than chasing strength: the FY26 setup looks back-half weighted, so the cleaner entry is any 3-5% drawdown on concerns about tariffs or destocking.
• Avoid shorting PG outright; if bearish on staples, express it through short CLX or a PG/CLX pair. CLX has less room to absorb pricing and restructuring simultaneously, so margin risk is higher.
• Long WMT and COST selectively against PG on a 3-6 month view: lower retailer inventories and trade-down behavior can benefit traffic and share, while suppliers bear the tariff and promo burden.
• Optionality trade: buy PG Jan-2027 calls or call spreads if you expect restructuring savings to show up in FY27. The risk/reward improves if the market underestimates the speed of overhead reduction and innovation-led reacceleration.